Jefferies Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $28
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $77 to $28.
Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $77 to $28.